Clinical Trial

ImproviNg rEnal Outcomes Following Coronary angiograPhy and/or percuTaneoUs coroNary intErventions

Study acronym: NEPTUNE
Recruiting
View on ClinicalTrials.gov →
Summary
The NEPTUNE triple-blind, active-placebo, adaptive, pragmatic, randomized trial aims to evaluate the effectiveness of a new intra-venous hydration strategy guided by left ventricular end-diastolic pressure (LVEDP), amount of contrast used, and baseline renal function, to prevent contrast-induced acute kidney injury (CI-AKI) and patient-oriented clinical endpoints in all-comer patients undergoing coronary angiogram and/or percutaneous coronary intervention (PCI).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-06-15; most recent amendment 2025-12-01.
Status change: Not Yet Recruiting → Recruiting 2021-07-02
Trial Details
NCT Number NCT04936607
Lead Sponsor Montreal Heart Institute
Collaborators: Université de Montréal, Canadian Institutes of Health Research (CIHR)
Conditions Contrast-Induced Acute Kidney Injury
Enrollment 1,158 participants
Start Date 2021-06-28
Primary Completion 2027-01-30 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-08